ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Regenerx Biopharmaceuticals

Regenerx Biopharmaceuticals (RGN)

0.00
0.00
(0.00%)
At close: March 28 04:00PM
0.00
0.00
( 0.00% )

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
-
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
-
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

RGN Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QLIQilian International Holding Group Ltd
$ 1.03
(49.30%)
2.18M
SBFMSunshine Biopharma Inc
$ 0.0886
(46.45%)
15.47M
NUWENewellis Inc
$ 0.4002
(12.57%)
33.53k
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.209
(12.37%)
469.91k
XLOXilio Therapeutics Inc
$ 1.1996
(11.07%)
615.67k
XTKGX3 Holdings Company Ltd
$ 0.66
(-33.34%)
880.38k
WATTEnergous Corporation
$ 1.69
(-16.75%)
7.23k
APLTApplied Therapeutics Inc
$ 5.90
(-13.24%)
84.69k
VVOSVivos Therapeutics Inc
$ 4.20
(-13.04%)
14.87k
RNACCartesian Therapeutics Inc
$ 0.58
(-10.77%)
27.78k
SBFMSunshine Biopharma Inc
$ 0.0886
(46.45%)
15.47M
CRKNCrown Electrokinetics Corporation
$ 0.06
(0.17%)
4.82M
AAPLApple Inc
$ 171.23
(-0.15%)
3.2M
MSFTMicrosoft Corporation
$ 420.00
(-0.17%)
2.51M
INTCIntel Corporation
$ 44.11
(-0.14%)
2.34M

RGN Discussion

View Posts
The Night Stalker The Night Stalker 14 years ago
this stocks looks even better than before, the volumes picking up
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
this stock will pop big one day for now it sits stuck at .26
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
sure is but this company is low on cash, expect to see many more offerings to come, that or a partner.
๐Ÿ‘๏ธ0
ikingulu ikingulu 14 years ago
RGN under 30 cents is a bargain
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
should be a big gainer in a year or 2, this companys on the right track with their research
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
This Article:
British Researchers Report that TB4 is Essential to Heart Development
Date : 08/02/2010 @ 8:30AM
Source : Business Wire
Stock : RegeneRx Biopharmaceuticals, Inc. (RGN)
Quote : 0.283 0.017 (6.39%) @ 4:15PM



British Researchers Report that TB4 is Essential to Heart Development
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
1 Month : July 2010 to August 2010

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (โ€œthe Companyโ€ or โ€œRegeneRxโ€) today announced that a research team from the Molecular Medicine Unit at UCL-Institute of Child Health in London reported preclinical findings that Thymosin beta 4 (TรŸ4), is essential to healthy heart development and embryonic survival.

The research was conducted by Drs. Nicola Smart, Karina Dubé and Paul Riley, and was published online in Nature Communications; 2010 Jul 27; DIO 10.1038/ncomms1041. The research was performed under a Material Transfer Agreement between RegeneRx Biopharmaceuticals, Inc. and the UCL-Institute.

In the study, mice embryos were genetically modified not to produce Hand1, a key transcription factor that plays a fundamental role in the normal development of the heart and in congenital heart disease. Without Hand1, TรŸ4 is down-regulated, hearts are malformed and the embryos do not survive. In this study, injection of synthetic TรŸ4 into pregnant female mice lacking Hand1 resulted in normal development and in the survival of the early embryos. This paper provides the first direct evidence that TรŸ4 plays a critical role in early embryonic vessel development and identifies a novel Hand-1-TรŸ4 pathway.

โ€œThese findings are important in that they establish the molecular mechanism by which TรŸ4 stimulates vascular growth of the embryo and opens up the possibility of utilizing TรŸ4 to potentially correct serious heart defects in utero,โ€ stated Allan Goldstein, Ph.D., Professor of Biochemistry and Molecular Biology at The George Washington University School of Medicine and Founder and Chief Scientific Advisor of RegeneRx.

โ€œWe believe this research further supports development of RGN-352, an injectable formulation of TรŸ4, in acute myocardial infarction,โ€ said J.J. Finkelstein, Chief Executive Officer of RegeneRx. โ€œWe plan to begin a Phase 2 study in AMI later this year.โ€

About TรŸ4
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
put RGN back on your radar surf, i like this company and their amazing science they got going on, this can run again just needs some volume
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
yes it is
๐Ÿ‘๏ธ0
mlkrborn mlkrborn 14 years ago
Armani emporium; Is it a technical reading?
tia
GL!
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
in for a swing, once RGN breaks .29 it runs to .34- .40 easily
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
key break of .29 sends it, i believe a run is brewing
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
this stock has been beaten up enough, its up from here, key break of .29 sends it
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
charts are too good to pass up, looking for a pop next week
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
in for a swing, looks cheap down here
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
key break of .29 sends it IMO
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
i went ahead and loaded up RGN today, i like the news the other day

Researchers Report in Neuroscience that TB4 Improves Neurological Function after Stroke
Date : 07/19/2010 @ 12:30PM
Source : Business Wire
Stock : RegeneRx Biopharmaceuticals, Inc. (RGN)
Quote : 0.284 0.012 (4.41%) @ 11:05AM



Researchers Report in Neuroscience that TB4 Improves Neurological Function after Stroke
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
1 Month : June 2010 to July 2010

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (โ€œthe Companyโ€ or โ€œRegeneRxโ€) today announced a research team from the Henry Ford Hospital in Detroit, MI, reported that Thymosin beta 4 (TรŸ4), administered to rats after embolic stroke, improved neurological functional outcome compared to control animals.

The research was conducted by Dr. Daniel Morris and his colleagues at the Department of Emergency Medicine, Henry Ford Health System, Detroit, MI, and published in Neuroscience, 2010 Aug 25 169(2) 674-682, http://www.ncbi.nlm.nih.gov/pubmed/20627173. The research was performed under a Material Transfer Agreement between RegeneRx Biopharmaceuticals, Inc. and the Henry Ford Health System.

Improvement in neurological function was measured at various time intervals over a seven week period and was statistically significant. A statistically significant increase in remyelination of axons and vessel density in the ischemic boundary was also observed between rats receiving TรŸ4 vs. controls, likely due to an increased mobilization of oligodendrocyte progenitor cells (brain stem cells that differentiate into cells that protect nerve fibers). mRNA levels for the epidermal growth factor receptor were determined in both normal and stroke rats treated with TรŸ4 and were approximately 50% higher in the stroke-treated rats. This receptor has previously been shown to be a key regulator of progenitor cell expansion and tissue regeneration in response to brain injury and further confirms the role of TรŸ4 in stem cell-mediated tissue repair.

โ€œSome of these data were previously reported at an International Stroke Conference in March; however, the data published today include more specific information on functional remodeling and potential mechanisms of action related to recruitment and differentiation of oligodendrocyte progenitor cells. These data are compelling and elaborate previously reported data in EAE mice (experimental models for multiple sclerosis) and in traumatic brain injury in rats showing that TรŸ4 can effect regeneration of neuronal cells after injury. In this experiment, after an ischemic stroke, neurological function in the rat models was significantly improved, apparently by remyelination of neurological axons (nerve fibers that conduct electrical signals) induced by TรŸ4. The fact that TรŸ4 helps repair and regenerate tissue after a brain injury strongly correlates with other published data showing TรŸ4โ€™s ability to regenerate neuronal and cardiac tissue after ischemic events,โ€ stated Dr. Hynda Kleinman, former head of cell biology at the National Institute of Dental and Craniofacial Research, NIH, and a consultant to RegeneRx.

About TรŸ4

TรŸ4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-functional molecule that has been shown in pre-clinical studies to promote endothelial cell differentiation and migration in the heart and central nervous system, promote angiogenesis in dermal and cardiac tissues, increase keratinocyte migration and collagen deposition, and decrease inflammation by down-regulating inflammatory cytokines. RegeneRx has identified several molecular variations of TรŸ4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health and various academic researchers throughout the world have published numerous scientific articles in high impact journals indicating TรŸ4โ€™s in vitro and in vivo efficacy in accelerating wound healing and tissue protection and regeneration under a variety of conditions. Abstracts of scientific papers related to TรŸ4โ€™s mechanisms
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
RGN- the buys are looking good today, i bought 5,000 shares just now

33k buys verses 13k sells

http://ih.advfn.com/p.php?pid=trades&symbol=RGN
๐Ÿ‘๏ธ0
wesley_ wesley_ 14 years ago
put it on watch, thx!
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
hey wes put RGN back in your radar screens
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
looks like the dilution has ended? churning nicely down here
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
hey surf, do you follow RGN anymore? do you see a big run in this
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
8:34AM Regenerex Biopharam announced that a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery (RGN) 0.34 : Co announced that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, scientists found that the systemic administration of thymosin beta 4, or Tb4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.
๐Ÿ‘๏ธ0
DFW DFW 14 years ago
filing to change Authorized from 100 million to 200 million

with the Outstanding 60,406,828 but a very small Float of 2,627,539 makes me think some major share structure on the way....

200 million is in line with a lot of these type companies I have been looking at...maybe they are just getting ready for the future.

With a float that small this ought hop like a frog is there was good news....

Are they out of money? Dilution on the way?


.
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
http://www.nasdaq.com/asp/quotes_sec.asp?symbol=rgn&selected=rgn
๐Ÿ‘๏ธ0
DFW DFW 14 years ago
Wonder how these numbers will change...

Shares Outstanding 60.41 M
Float 2.63 M

price should go down until this closes..??
my guess
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
1:45AM RegeneRx Biopharma announces proposed public offering (RGN) 0.58 : Co intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering. The number of units to be issued, the price of each unit, the portion of a common share underlying each warrant and the exercise price per warrant, as well as the size of the offering, will be determined at the time of pricing the offering.
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
New T4 Eye Data to be Presented at ARVO Meeting

Press Release Source: RegeneRx Biopharmaceuticals, Inc. On Thursday April 8, 2010, 8:30 am EDT
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.regenerx.com&esheet=6242329&lan=en_US&anchor=www.regenerx.com&index=1&md5=37474c0a84dd2105c087e77f59ba9832) announced today that TรŸ4, a synthetic version of a naturally occurring peptide that is the basis for the companyโ€™s product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010. The presentations will review results of research performed using TรŸ4 in the field of ophthalmology and will describe potential uses of TรŸ4, including for the first time, as a drug embedded in a bandage contact lens.

In the first presentation, โ€œDeveloping a Bandage Contact Lens Delivery System for Controlled Release of Thymosin Beta 4 to the Corneal Epithelium,โ€ Dr. Gabriel Sosne and his research team at Wayne State University School of Medicine in Detroit, Michigan will describe research performed to evaluate the potential for extended release of TรŸ4 for more than 100 hours. The researchers concluded that a bandage contact lens delivery system would be a novel, feasible and potentially useful way to promote direct application and extended release of TรŸ4 to the surface of the eye. Dr. Sosne is Associate Professor of Ophthalmology at Wayne State University School of Medicine, Department of Ophthalmology and Anatomy/Cell Biology in Detroit, Michigan. He is also a member of RegeneRx's scientific advisory board.

The second presentation, โ€œAntioxidative Effect of Thymosin Beta 4 for Porcine Trabecular Meshwork,โ€ will discuss results of research that was designed to evaluate the antioxidative effect of administering TรŸ4 to trabecular meshwork cells in a pig model. These cells make up tissue inside the anterior (front) part of the eye that is responsible for draining most of the fluid from the eye. The degree of fluid drainage and oxidative stress may be associated with increased intraocular pressure and glaucoma, which can injure the optic nerve. The researchers in this study determined that extracellular TรŸ4 has an antioxidative effect for hydrogen peroxide in the porcine trabecular meshwork cells. These findings may be relevant to reducing oxidative stress in these cells, which could potentially reduce the damage to the eye from glaucoma. The research was conducted at the departments of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine in Kyoto, Japan and Kumamoto University Graduate School of Medicine in Kumamoto, Japan.

A third presentation, โ€œA Randomized, Double-Mask, Placebo-Controlled, Dose-Response, Phase 2 Study of the Safety and Efficacy of Thymosin beta 4 in the Treatment of Diabetic Patientsโ€™ Corneal Wounds Resulting from Epithelial Debridement During Vitrectomy,โ€ will report on the clinical results from the companyโ€™s Phase 2 clinical trial of its product candidate RGN-259 in patients with corneal wounds. The particular patients for whom results will be reviewed were those patients who received either the lowest dose of TรŸ4 or placebo in the trial. The study was closed by RegeneRx after enrollment of the low-dose cohort due to slow patient accrual, in addition to emerging proof-of-concept data generated in compassionate-use clinical trials in patients with non-healing eye ulcers. As previously reported, the research team observed no serious adverse events following administration of RGN-259 and no statistical differences in the time to wound healing when comparing TรŸ4 to placebo. The researchers did note that there appeared to be increased thickening of the corneal epithelium and reduced inflammation (cell and flare) seen in TรŸ4-treated patients. These observations would be indicative of corneal re-epithelialization and wound healing and are consistent with known cell migratory and anti-inflammatory properties of TรŸ4. The principal investigator of the study was Dr. Benni H. Jeng, Chief, Department of Ophthalmology at the San Francisco General Hospital and Associate Professor and Co-Director, Cornea Service, University of California San Francisco Department of Ophthalmology and Francis I. Proctor Foundation.

โ€œTaken together, the rapidly progressing research advancements in the eye with TรŸ4 are bringing the goal of making TรŸ4 a novel therapy for a number of ocular disorders closer to reality,โ€ commented Dr. Sosne.
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 14 years ago
this ones a winner
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
8:56AM Regenerex Biopharam: Researchers report that Thymosin beta 4 improves neurological function after stroke (RGN) 0.62 : Co announces that a research team from the Henry Ford Hospital in Detroit, MI reported that Thymosin beta 4, administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals. Improvement in neurological function was measured at various time intervals over a seven week period and was statistically significant. An increase in remyelination of axons was observed in rats receiving Tb4 compared to control animals, likely due to an increased mobilization of oligodendrocyte progenitors that differentiate into mature myelin-producing oligodendrocytes. In cell culture, Tb4 treated neuronal progenitor cells isolated from normal and stroke rats demonstrated increased mRNA levels of epidermal growth factor receptor. This receptor has previously been shown to be a regulator of oligoprogenitor cell expansion and tissue regeneration in response to brain injury and further supports the role of Tb4 in stem cell-mediated tissue repair
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
9:00AM Regenerex Biopharam announces researchers report novel biological properties of fragments of Thymosin Beta 4 (RGN) 0.60 : Co announced that a university research team has published an article ahead of print in FASEB Journal, a high-impact scientific journal, describing novel biological properties of several Thymosin beta 4 (Tb4) peptide fragments. The researchers summarize related published studies and report on their work showing that Tb4 and these smaller peptides were able to block inflammation, reduce fibrosis, promote cell survival and block apoptosis, stimulate stem/progenitor cell differentiation, induce angiogenesis, and promote cell migration. Other activities include the induction of various genes encoded for important proteins involved in cell development (such as laminin-5, MMPs, TGF beta, zyxin, terminal deoxynucleotidyl transferase, and angiogenesis-related proteins) and activate signaling pathways that influence cell and tissue survival (such as ILK/PINCH/Akt).
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
8:36AM On The Wires : Regenerex (RGN) announces that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tb4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. No effects related to muscle function or fibrosis and no adverse reactions were observed in the mice... ZOLL Medical Corporation (ZOLL) announces that SAMU Brasilia has equipped its ambulances with the AutoPulse Non-Invasive Cardiac Support Pump. SAMU Brasilia has installed AutoPulse units in its fleet of ambulances, one for each vehicle plus four spare training boards, in a contract valued at $500,000 (U.S.). The AutoPulse was granted health clearance in January 2009 and is the only automatic chest compression system available for sale in Brazil.
๐Ÿ‘๏ธ0
momentum74 momentum74 14 years ago
in for a bounce
๐Ÿ‘๏ธ0
surf1944 surf1944 14 years ago
8:30AM Regenerex Biopharam announces final clinical results from Phase I Trial with RGN-352 (RGN) 0.60 : The co announces that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB. There were no adverse events judged to be associated with administration of RGN-352, which was deemed to be well-tolerated. The results of the trial will be published in the Annals of the New York Academy of Sciences, and a clinical study report will be forwarded to the FDA. RGN-352 is an injectable formulation of thymosin beta 4 (Tb4) peptide. RegeneRx will utilize this data to support a Phase II cardiovascular clinical trial in patients immediately after ST-elevation myocardial infarction (acute heart attack), based upon numerous published scientific papers indicating Tb4's ability to improve heart function and reduce myocardial damage in various animal models after an induced ischemic heart attack. Based on these data, it is the company's belief that RGN-352 may offer the same benefit in patients when administered shortly after unblocking the occluded vessel responsible for the infarction.
๐Ÿ‘๏ธ0
wesley_ wesley_ 14 years ago
I just saw, Cavazza also added 1,219,512 shares of common stock at $ 0.82, filed in form 4 today, now... I'm with him..., must be something brewing..., if he purchased RGN shares worth 1 million $$$
๐Ÿ‘๏ธ0
wesley_ wesley_ 14 years ago
volume is huge today...
๐Ÿ‘๏ธ0
wesley_ wesley_ 14 years ago
volume alert! showing some action today... :)
๐Ÿ‘๏ธ0
mlkrborn mlkrborn 14 years ago
It was a significant progress yet short pricks oversold it next day after being squeezed hard -- as usual!
GLLs
๐Ÿ‘๏ธ0
pj McMulligan pj McMulligan 14 years ago
September 29, 2009 - 11:42 AM EDT

RegeneRx's Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model

Sep. 29, 2009 (Business Wire) -- REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery. In addition to this neurological benefit, the researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath), the control of which are important therapeutic goals.

The study entitled, “Neurological Functional Recovery after Thymosin Beta 4 Treatment in Mice with Experimental Auto Encephalomyelitis,” was published online ahead of print in Neuroscience, 2009 September 24. The publication highlights the statistically significant effects of Tβ4 treatment in EAE mice, including improvement of neurological functional recovery, reduction of inflammatory infiltrates in the brain, and increase of oligodendrocyte progenitor cells (a type of stem cell) and mature oligodendrocytes in the brain.

The research team was led by Jing Zhang, MD, PhD; Zheng Gang Zhang, MD, PhD; Dan Morris, MD; Yi Li, MD; Cynthia Roberts, Stanton B. Elias, MD, and Michael Chopp, PhD of the Departments of Neurology and Emergency Medicine at the Henry Ford Health System in Detroit, Michigan and the Department of Physics at Oakland University in Rochester, Michigan.

Multiple Sclerosis (MS)

There is no cure for MS. While considerable progress has been made in the recent years with the development of anti-inflammatory and immunomodulatory therapies, there are currently no effective repair therapies routinely used in multiple sclerosis patients. Clinical trials have clearly demonstrated that an anti-inflammation treatment approach alone is insufficient in preventing or ameliorating permanent and accumulating MS deficits. Moreover, many medications have serious side effects and some carry significant risks. Oligodendrogenesis/remyelination is an important therapeutic goal and the subject of the research described in the journal article.

Tβ4 and RGN-352

Tβ4 peptide is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. RegeneRx has identified several molecular variations of Tβ4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions in the U.S., have published scientific articles indicating Tβ4’s in vitro and in vivo efficacy in accelerating wound healing and tissue protection under a variety of conditions. Abstracts of scientific papers related to Tβ4's mechanisms of action may be viewed at RegeneRx's web page: www.regenerx.com.

RGN-352 is an injectable formulation of Tβ4 that has just completed Phase I clinical trials and has been shown to be safe and well-tolerated. The product candidate has been developed to address medical indications where systemic administration is warranted. RegeneRx is currently planning a Phase II clinical trial to evaluate RGN-352 in post-acute myocardial infarction (heart attack) patients, although other indications such as stroke, ischemic renal disease, and certain ulcerative and autoimmune conditions have been identified as potential targets.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. RegeneRx is also developing RGN-457 for use in pulmonary indications such as cystic fibrosis. These product candidates are based on Tβ4, a synthetic copy of a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to novel peptides.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Examples of such forward-looking statements include statements concerning any future development efforts for RGN-352 as a treatment for stroke, multiple sclerosis, or other neurological indications, the results of future trials involving Tβ4, and the therapeutic potential of Tβ4 for neurological indications, or its use in other pharmaceutical or consumer products. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that RegeneRx’s product candidates may not demonstrate safety and/or efficacy in its ongoing or future clinical trials and other development efforts, including its trials and/or other development efforts related to RGN-137, RGN-259, RGN-352 and RGN-457, the risk that RegeneRx or its collaborators will not obtain approval to market RegeneRx’s product candidates in the U.S. or abroad, the risks associated with RegeneRx’s need for additional financing to meet capital requirements necessary for the further development and commercialization activities relating to RegeneRx’s product candidates, the risks associated with protecting RegeneRx’s intellectual property, or that RegeneRx will not be able to obtain patent protection, or that its issued patents will be infringed, and such other risks described in RegeneRx’s annual report on Form 10-K for the year ended December 31, 2008 and quarterly report on Form 10-Q for the period ended March 31, 2009, and other filings RegeneRx makes with the SEC. Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. RegeneRx undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


Source: Business Wire (September 29, 2009 - 11:42 AM EDT)
๐Ÿ‘๏ธ0
pj McMulligan pj McMulligan 14 years ago
Added this morning @.84 ask to the RGN stack~ glad i did! ;) chart looking prime here fellas

๐Ÿ‘๏ธ0
mlkrborn mlkrborn 14 years ago
Nice response in PPS..
๐Ÿ‘๏ธ0
Trader0327 Trader0327 14 years ago
RegeneRx's T4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
NEWS:

Press Release
Source: RegeneRx Biopharmaceuticals, Inc.
On Tuesday September 29, 2009, 11:42 am EDT
Buzz up! 0Print.Companies:Regenerx Biopharmaceuticals Inc.
BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery. In addition to this neurological benefit, the researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath), the control of which are important therapeutic goals.

http://finance.yahoo.com/news/RegeneRxs-T4-Significantly-bw-377571417.html?x=0&.v=1
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 15 years ago
http://www.regenerx.com/wt/home/index

Nice pipeline of drugs, this is worth big money one day
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 15 years ago
Nice news under the radar type play that will run hard
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 15 years ago
The next mega runner bio is RGN

http://stockcharts.com/h-sc/ui?s=rgn&p=D&b=5&g=0&id=p23463897154

once that red line and blue line cross this pops big
๐Ÿ‘๏ธ0
ZoZoStockWatch ZoZoStockWatch 15 years ago
.
๐Ÿ‘๏ธ0
wolfster1 wolfster1 15 years ago
This company is mighty impressive. I am buying.
๐Ÿ‘๏ธ0
pj McMulligan pj McMulligan 15 years ago
In today with 100DMA breakout, ParSar buy signal, and positive Trix 3~ Lookin good here! :)

๐Ÿ‘๏ธ0
dominos3265 is a punk dominos3265 is a punk 15 years ago
Patience!
๐Ÿ‘๏ธ0
kutie kutie 15 years ago
u r a POS stock!!!

ok u r not. but the results not so encouraging.

good luck nxt t!

NEWSSSSS-

http://biz.yahoo.com/bw/090109/20090109005243.html?.v=1
๐Ÿ‘๏ธ0
kutie kutie 15 years ago
dont feel lonely- rgn

1 day some1 else will notice u r a precious little gem :)
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock